Arecor Therapeutics plc (LON:AREC – Get Free Report)’s stock price traded up 6.1% during trading on Thursday . The stock traded as high as GBX 70 and last traded at GBX 70. Approximately 12,959 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 23,612 shares. The stock had previously closed at GBX 66.
Arecor Therapeutics Price Performance
The business’s 50-day simple moving average is GBX 62.84 and its two-hundred day simple moving average is GBX 66.55. The stock has a market cap of £26.43 million, a price-to-earnings ratio of 35.00 and a beta of -0.18. The company has a debt-to-equity ratio of 1.52, a current ratio of 4.35 and a quick ratio of 6.24.
About Arecor Therapeutics
Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.
Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.
Further Reading
- Five stocks we like better than Arecor Therapeutics
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Arecor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arecor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
